welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Comparison of Nonampullary Duodenal Adenomas in Patients with Familial Adenomatous Polyposis Versus Patients with Sporadic Adenomas
source: Gastrointestinal Endoscopy
authors: Cassani LS, Lanke G, Chen HC, Wang X, Lynch P, Lee JHsummary/abstract:
BACKGROUND AND AIMS:
Nonampullary duodenal adenomas are either sporadic or associated with a hereditary syndrome such as familial adenomatous polyposis (FAP). The aim of this study is to compare characteristics and outcomes of sporadic and FAP-associated duodenal adenomas.
We retrospectively collected clinical, endoscopic, and pathologic data in patients diagnosed with duodenal adenomas at our institution and included all available follow-up.
Two hundred thirteen subjects were identified; 118 had FAP and 95 had sporadic adenomas. FAP subjects were more likely to have multifocal disease. Initial size was not significantly associated with dysplasia. Fourteen (12%) with FAP and 33 (35%) with sporadic adenomas underwent EMR. Among those subjects who did not undergo EMR or surgery, there was no difference between the FAP and sporadic groups with progression to new dysplasia or cancer. However, the FAP group was significantly more likely to have dysplasia at follow-up (P = .05). There was a significant difference in overall survival between the FAP and sporadic groups (log-rank test, P < .001). In the subgroup of patients aged 40 years old and older who did not undergo intervention, the FAP group had a shorter time to pathology progression compared with the similar sporadic subgroup. Range of time to progression to cancer was 3 to 161 months.
FAP subjects were more likely to be younger and have multifocal disease. Progression of pathology was more likely in the older FAP group compared with the sporadic group. Time to progression to cancer was widely variable and, therefore, unpredictable.organization: MD Anderson Cancer Center, Emory University
read more full text source
expertly curated content related to this topic
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of...This phase II trial studies the side eff...
ESMO Consensus Guidelines For Management of Patients with Colon and Rectal Cancer, A Personalized Approach to Clinic...Colorectal Cancer (CRC) is the most comm...
Intraductal Papillary and Mucinous Pancreatic Tumour: A New Extracolonic Tumour in Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) is ...
Desmoid Tumour in Familial Adenomatous Polyposis Patients: Responses to TreatmentsNo guidelines for desmoid tumors (DT) ma...
23-year-old Mount Airy woman to spend lifetime with cancerAn incurable cancer has touched every pa...
Familial Risk and Heritability of Cancer Is Higher Among TwinsTwins carry a significant excess familia...
Acute Pancreatitis as the Initial Manifestation of an Adenocarcinoma of the Major Duodenal Papilla in a Patient With...We report a case of an ampullary carcino...